Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Trial Parameters
Brief Summary
The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not progressed following neoadjuvant chemotherapy plus Tislelizumab ± Bevacizumab and definitive concurrent chemoradiation therapy.
Eligibility Criteria
Inclusion Criteria: * For inclusion in neoadjuvant therapy, patients should fulfil the following criteria: * Provision of signed, written and dated informed consent prior to any study specific procedures; * Male or female aged 18\~75 years old; * Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced (Stage III) disease; * Without prior chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy; * A recent tumour biopsy (taken following completion of the most recent therapy) is an optional requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk; * Life expectancy ≥12 weeks; * World Health Organization (WHO) Performance Status of 0 or 1; * Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 14 days before the use of study drug (HCG has a minimum sensitivity of 25 IU/L or equival